Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite and body weight, while tesamorelin is a growth hormone-releasing hormone analogue that stimulates pituitary GH release to reduce visceral fat, primarily in HIV-positive patients with lipodystrophy
Another GLP-1 analog, liraglutide (Saxenda), was FDA-approved for weight loss in 2014
228 Histone deacetylation is considered to be the inhibition of DNA assembly by chromatin condensation and transcription factors, resulting in transcriptional inhibition
[24] [25] Individuals with MEN 2 carry germline RET mutations conferring near-100% lifetime risk of developing MTC, often presenting in childhood or early adulthood
This mechanism contributes to their weight loss benefits
Schedule: Daily subcutaneous injections for 1226 weeks (extendable to 52 weeks with medical supervision) [3]